巴瑞替尼长期单药或联合甲氨蝶呤治疗类风湿关节炎的疗效与安全性
该研究为RA-BEGIN研究的事后分析,评估早期活动性类风湿关节炎(RA)患者进入长期扩展研究RA-BEYOND后继续巴瑞替尼单药或加用甲氨蝶呤的疗效与安全性,随访至24周。结果显示继续单药或换用单药的患者疾病控制持续或改善,基线疾病活动较高者加用甲氨蝶呤后活动改善,各组安全性相似。
要点
- 巴瑞替尼单药持续或换用单药治疗可使多数患者疾病控制持续或改善。
- 基线疾病活动较高的患者加用甲氨蝶呤后疾病活动改善。
- 各治疗组安全性结局相似。
核心结论
- 多数患者继续巴瑞替尼单药或从甲氨蝶呤单药或巴瑞替尼联合甲氨蝶呤换为巴瑞替尼单药后应答良好,疾病控制持续或改善。
- 在原治疗方案下疾病控制欠佳的患者加用甲氨蝶呤后疾病控制持续或改善。
研究设计与样本
- RA-BEGIN研究的事后分析,纳入进入长期扩展研究RA-BEYOND并评估至24周的患者。
- RA-BEGIN中未使用过甲氨蝶呤的早期活动性RA患者随机接受甲氨蝶呤单药、巴瑞替尼4mg单药或巴瑞替尼4mg联合甲氨蝶呤治疗。
- 第52周进入RA-BEYOND时所有患者接受巴瑞替尼4mg单药,甲氨蝶呤可由研究者酌情处方。
主要发现
- RA-BEYOND中未在RA-BEGIN阶段接受救援治疗的患者(n=423)被评估。
- 47%继续巴瑞替尼单药,53%加用甲氨蝶呤,来自3个原始治疗组的比例相似。
- RA-BEYOND基线疾病活动较低的患者继续巴瑞替尼单药通常维持良好,评估指标包括简化疾病活动指数、临床疾病活动指数和健康评估问卷残疾指数。
- 处方甲氨蝶呤的患者在RA-BEYOND基线疾病活动较高,加用甲氨蝶呤后疾病活动改善。
- 安全性结局在各治疗组间相似。
临床怎么用
- 对于巴瑞替尼单药治疗后疾病控制良好的RA患者,可继续单药维持。
- 对于原治疗方案下疾病控制欠佳的患者,加用甲氨蝶呤可能改善疾病控制。
局限性
- 本研究为事后分析,评估时间至24周。
- 甲氨蝶呤的使用由研究者酌情决定,非随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy. METHODS: This is a post hoc analysis of patients from the RA-BEGIN study who entered a long-term extension, RA-BEYOND, and were assessed for up to 24 weeks. In RA-BEGIN, MTX-naive patients with early active RA were randomized to MTX monotherapy, baricitinib 4 mg monotherapy, or baricitinib 4 mg plus MTX. At week 52, all patients entering RA-BEYOND received baricitinib 4 mg monotherapy. MTX could be prescribed during RA-BEYOND at the investigator's discretion. RESULTS: Patients in RA-BEYOND who were not rescued in RA-BEGIN (n = 423) were evaluated. Of these, 47% continued baricitinib monotherapy and 53% added MTX, with similar proportions from the 3 original arms. Patients with lower disease activity at the RA-BEYOND baseline generally continued to do well with baricitinib monotherapy as assessed by the Simplified Disease Activity Index, the Clinical Disease Activity Index, and the Health Assessment Questionnaire disability index scores. Patients prescribed MTX had higher disease activity at the RA-BEYOND baseline and had improved disease activity after the addition of MTX. Safety outcomes were similar across treatment groups. CONCLUSION: Many patients responded well to continued baricitinib monotherapy or to switching to baricitinib monotherapy from MTX monotherapy or baricitinib plus MTX, showing sustained or improved disease control. The groups of patients who had less disease control on their original therapies showed sustained or improved disease control with the addition of MTX to baricitinib.
引用
- Fleischmann R, Takeuchi T, Schiff M, et al. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care Res (Hoboken). 2020. PMID: 31233281. doi:10.1002/acr.24007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。